135 related articles for article (PubMed ID: 38315477)
21. Triptan use in elderly over 65 years and the risk of hospitalization for serious vascular events.
Tran PT; Lapeyre-Mestre M; Berangere B; Lanteri-Minet M; Palmaro A; Donnet A; Micallef J
J Headache Pain; 2024 Apr; 25(1):68. PubMed ID: 38671362
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Reclassifying Triptans in Australia: Application of an Economic Evaluation Approach to Regulatory Decisions.
Parkinson B; Gumbie M; Cutler H; Gauld N; Mumford V; Haywood P
Value Health; 2019 Mar; 22(3):293-302. PubMed ID: 30832967
[TBL] [Abstract][Full Text] [Related]
23. [Frovatriptan possibly causing acute myocardial infarction].
Møller-Helgestad OK; Kaltoft AK; Kasch H
Ugeskr Laeger; 2015 Mar; 177(13):V10140537. PubMed ID: 25822816
[TBL] [Abstract][Full Text] [Related]
24. Triptans for Acute Migraine Headache: Current Experience With Triptan Use and Prescription Habits in a Tertiary Care Headache Outpatient Clinic: An Observational Study.
Fischer M; Frank F; Wille G; Klien S; Lackner P; Broessner G
Headache; 2016 Jun; 56(6):952-60. PubMed ID: 27091593
[TBL] [Abstract][Full Text] [Related]
25. [Myocardial infarction in a patient free of coronary artery disease].
Ekström K; Lönnberg A; Anttonen O
Duodecim; 2016; 132(11):1069-73. PubMed ID: 27400593
[TBL] [Abstract][Full Text] [Related]
26. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
27. Risk of ischemic complications related to the intensity of triptan and ergotamine use.
Wammes-van der Heijden EA; Rahimtoola H; Leufkens HG; Tijssen CC; Egberts AC
Neurology; 2006 Oct; 67(7):1128-34. PubMed ID: 17030745
[TBL] [Abstract][Full Text] [Related]
28. Acute treatment patterns in patients with migraine newly initiating a triptan.
Lipton RB; Marcus SC; Shewale AR; Dodick DW; Viswanathan HN; Doshi JA
Cephalalgia; 2020 Apr; 40(5):437-447. PubMed ID: 32138526
[TBL] [Abstract][Full Text] [Related]
29. Association Between Intracerebral Hemorrhage and Subsequent Arterial Ischemic Events in Participants From 4 Population-Based Cohort Studies.
Murthy SB; Zhang C; Diaz I; Levitan EB; Koton S; Bartz TM; DeRosa JT; Strobino K; Colantonio LD; Iadecola C; Safford MM; Howard VJ; Longstreth WT; Gottesman RF; Sacco RL; Elkind MSV; Howard G; Kamel H
JAMA Neurol; 2021 Jul; 78(7):809-816. PubMed ID: 33938907
[TBL] [Abstract][Full Text] [Related]
30.
Martínez-Pías E; García-Azorín D; Minguez-Olaondo A; Trigo J; Sierra Á; Ruiz M; Guerrero ÁL
Expert Rev Neurother; 2021 Jan; 21(1):123-130. PubMed ID: 33111580
[No Abstract] [Full Text] [Related]
31. Triptan education and improving knowledge for optimal migraine treatment: an observational study.
Baron EP; Markowitz SY; Lettich A; Hastriter E; Lovell B; Kalidas K; Dodick DW; Schwedt TJ;
Headache; 2014 Apr; 54(4):686-97. PubMed ID: 24520930
[TBL] [Abstract][Full Text] [Related]
32. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
33. Zolmitriptan induced acute coronary syndrome: a unique case.
Smith M; Golwala H; Lozano P
Am J Ther; 2011 Sep; 18(5):e153-6. PubMed ID: 21869671
[TBL] [Abstract][Full Text] [Related]
34. [Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
Perearnau P; Vuillemet F; Schick J; Weill G
Rev Neurol (Paris); 2006 Mar; 162(3):347-57. PubMed ID: 16585890
[TBL] [Abstract][Full Text] [Related]
35. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis.
Marchenko A; Etwel F; Olutunfese O; Nickel C; Koren G; Nulman I
Headache; 2015 Apr; 55(4):490-501. PubMed ID: 25644494
[TBL] [Abstract][Full Text] [Related]
36. Prenatal triptan exposure and parent-reported early childhood neurodevelopmental outcomes: an application of propensity score calibration to adjust for unmeasured confounding by migraine severity.
Wood ME; Frazier JA; Nordeng HM; Lapane KL
Pharmacoepidemiol Drug Saf; 2016 May; 25(5):493-502. PubMed ID: 26554750
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
Blumenfeld AM; Goadsby PJ; Dodick DW; Hutchinson S; Liu C; Finnegan M; Trugman JM; Szegedi A
Headache; 2021 Mar; 61(3):422-429. PubMed ID: 33749826
[TBL] [Abstract][Full Text] [Related]
38. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients.
Tepper S; Allen C; Sanders D; Greene A; Boccuzzi S
Headache; 2003 Jan; 43(1):44-8. PubMed ID: 12864757
[TBL] [Abstract][Full Text] [Related]
39. Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.
Frisk P; Sporrong SK; Ljunggren G; Wettermark B; von Euler M
Eur J Clin Pharmacol; 2016 Jun; 72(6):747-54. PubMed ID: 26922586
[TBL] [Abstract][Full Text] [Related]
40. Risk for ischemic stroke and coronary heart disease associated with migraine and migraine medication among older adults.
McKinley EC; Lay CL; Rosenson RS; Chen L; Chia V; Colantonio LD; Muntner P; Urman R; Farkouh ME
J Headache Pain; 2021 Oct; 22(1):124. PubMed ID: 34645382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
